|Bid||2.4300 x 900|
|Ask||2.4600 x 1200|
|Day's Range||2.4203 - 2.6700|
|52 Week Range||0.4400 - 5.8500|
|Beta (5Y Monthly)||2.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET.
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc.
FRAMINGHAM, MA / ACCESSWIRE / December 14, 2020 / Xenetic Biosciences, Inc.